Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

252.86 -5.52 (-2.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst ↗
 
Via Benzinga
News headline image
Where Jazz Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: 
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Q3 ↗
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
News headline image
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate ↗
 
Via Benzinga
News headline image
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread ↗
The company just hired three new executives, likely putting a buyout in the rearview. 
Via Investor's Business Daily
News headline image
Cannabis Stocks Struggle Through Q2 2022 ↗
An overview of how cannabis stocks fared in Q2 and what investors should understand about the space. 
Via Talk Markets
News headline image
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study ↗
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. 
Via Benzinga
News headline image
Brazilian Fund Invests $19M In US Cannabis Stocks ↗
As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are... 
Via Benzinga
News headline image
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder ↗
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea... 
Via Benzinga
News headline image
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint ↗
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with... 
Via Benzinga
News headline image
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity ↗
 
Via Benzinga
News headline image
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises ↗
The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022. 
Via Benzinga
News headline image
This Pharmaceutical Company Is Moving Beyond CBD ↗
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... 
Via Benzinga
News headline image
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL ↗
Thomas Wesley Pentz, better known for his artistic name, Diplo, partnered with California cannabis beverage company Leisuretown, professional skateboarder Rob Dyrdek and cannabis supply chain company... 
Via Benzinga
News headline image
4 Analysts Have This to Say About Jazz Pharmaceuticals ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research ↗
The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans. 
Via Benzinga
News headline image
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization? ↗
The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals ↗
The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel... 
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
News headline image
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating ↗
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
News headline image
Jazz Pharmaceuticals's Return On Capital Employed Insights ↗
Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between... 
Via Benzinga
News headline image
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval? ↗
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. 
Via Benzinga
News headline image
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next? ↗
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY ↗
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022. 
Via Benzinga
News headline image
Jazz Pharmaceuticals: Q1 Earnings Insights ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.